Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Standard
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. / Gahrton, Gösta; Iacobelli, Simona; Björkstrand, Bo; Hegenbart, Ute; Gruber, Astrid; Greinix, Hildegard; Volin, Liisa; Narni, Franco; Carella, Angelo Michele; Beksac, Meral; Bosi, Alberto; Milone, Giuseppe; Corradini, Paolo; Schönland, Stefan; Friberg, Kristina; van Biezen, Anja; Goldschmidt, Hartmut; de Witte, Theo; Morris, Curly; Niederwieser, Dietger; Garderet, Laurent; Kröger, Nicolaus; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee.
in: BLOOD, Jahrgang 121, Nr. 25, 20.06.2013, S. 5055-63.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
AU - Gahrton, Gösta
AU - Iacobelli, Simona
AU - Björkstrand, Bo
AU - Hegenbart, Ute
AU - Gruber, Astrid
AU - Greinix, Hildegard
AU - Volin, Liisa
AU - Narni, Franco
AU - Carella, Angelo Michele
AU - Beksac, Meral
AU - Bosi, Alberto
AU - Milone, Giuseppe
AU - Corradini, Paolo
AU - Schönland, Stefan
AU - Friberg, Kristina
AU - van Biezen, Anja
AU - Goldschmidt, Hartmut
AU - de Witte, Theo
AU - Morris, Curly
AU - Niederwieser, Dietger
AU - Garderet, Laurent
AU - Kröger, Nicolaus
AU - EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee
PY - 2013/6/20
Y1 - 2013/6/20
N2 - Long-term follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few and controversial. This is an update at a median follow-up of 96 months of the European Group for Blood and Marrow Transplantation Non-Myeloablative Allogeneic stem cell transplantation in Multiple Myeloma (NMAM)2000 study that prospectively compares tandem autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous transplantation alone (auto). There are 357 myeloma patients up to age 69 years enrolled. Patients with an HLA-identical sibling were allocated to auto/RICallo (n = 108) and those without to auto alone (n = 249). At 96 months progression-free survival (PFS) and overall survival (OS) were 22% and 49% vs 12% (P = .027) and 36% (P = .030) with auto/RICallo and auto respectively. The corresponding relapse/progression rate (RL) was 60% vs 82% (P = .0002). Non-relapse mortality at 36 months was 13% vs 3% (P = .0004). In patients with the del(13) abnormality corresponding PFS and OS were 21% and 47% vs 5% (P = .026), and 31% (P = .154). Long-term outcome in patients with multiple myeloma was better with auto/RICallo as compared with auto only and the auto/RICallo approach seemed to overcome the poor prognostic impact of del(13) observed after autologous transplantation. Follow up longer than 5 years is necessary for correct interpretation of the value of auto/RICallo in multiple myeloma.
AB - Long-term follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few and controversial. This is an update at a median follow-up of 96 months of the European Group for Blood and Marrow Transplantation Non-Myeloablative Allogeneic stem cell transplantation in Multiple Myeloma (NMAM)2000 study that prospectively compares tandem autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous transplantation alone (auto). There are 357 myeloma patients up to age 69 years enrolled. Patients with an HLA-identical sibling were allocated to auto/RICallo (n = 108) and those without to auto alone (n = 249). At 96 months progression-free survival (PFS) and overall survival (OS) were 22% and 49% vs 12% (P = .027) and 36% (P = .030) with auto/RICallo and auto respectively. The corresponding relapse/progression rate (RL) was 60% vs 82% (P = .0002). Non-relapse mortality at 36 months was 13% vs 3% (P = .0004). In patients with the del(13) abnormality corresponding PFS and OS were 21% and 47% vs 5% (P = .026), and 31% (P = .154). Long-term outcome in patients with multiple myeloma was better with auto/RICallo as compared with auto only and the auto/RICallo approach seemed to overcome the poor prognostic impact of del(13) observed after autologous transplantation. Follow up longer than 5 years is necessary for correct interpretation of the value of auto/RICallo in multiple myeloma.
KW - Aged
KW - Disease-Free Survival
KW - Female
KW - Follow-Up Studies
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Male
KW - Middle Aged
KW - Multiple Myeloma
KW - Time
KW - Transplantation Conditioning
KW - Transplantation, Autologous
KW - Transplantation, Homologous
KW - Treatment Outcome
U2 - 10.1182/blood-2012-11-469452
DO - 10.1182/blood-2012-11-469452
M3 - SCORING: Journal article
C2 - 23482933
VL - 121
SP - 5055
EP - 5063
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 25
ER -